LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

Javier Cortés, S-B. Kim, W-P. Chung, S-A. Im, Y.H. Park, Roberto Hegg, Minjung Kim, L-M Tseng, Vanessa Petry, C-F. Chung, Hiroji Iwata, E.P. Hamilton, Giuseppe Curigliano, Binghe Xu, C. Lee, Y. Liu, Jillian Cathcart, Emarjola Bako, Sunil Verma, Sara A. Hurvitz